Weekly Spotlight
Medicare Advantage Prior Authorization: Federal Watchdogs, Investigators, and Lawmakers Converge
Federal watchdogs, investigative journalists, and lawmakers converged this week on a single conclusion: the three largest Medicare Advantage insurers — UnitedHealth, Humana, and CVS — are denying post-acute and long-term care at rates that cannot be explained by clinical criteria alone.
Two OIG reports released June 8 documented the pattern with federal authority. One found MA plans deny post-acute care requests at exceedingly high rates and that many denials are overturned on appeal. The second formally directed CMS to collect systematic data and investigate the three largest plans. STAT+ reported earlier on a suspicious denial timing pattern in which certain plans appeared to cluster denials near coverage boundaries and appeal favorable rulings at above-average rates. The NYT added patient-level documentation: seniors who have paid into Medicare for decades are being denied skilled nursing and rehabilitation care they believed was covered, with limited capacity to appeal or wait.
The physician and legislative response has been direct. The AMA and a bipartisan group of lawmakers formally pushed back on AI-driven denial tools, arguing automated systems lack the clinical judgment required for individual coverage determinations. A House committee moved legislation to restrict Medicare’s use of AI tools in prior authorization decisions.
CMS has not yet announced a formal investigation, but the OIG referral, investigative reporting, legislative action, and patient documentation now form a convergence of pressure that is difficult to ignore.
Sources: STAT+ · MedPage Today · Healthcare Dive · Becker’s Hospital Review · InsideHealthPolicy · MedCity News · New York Times · STAT+
Centers for Medicare and Medicaid Services (CMS)
CMS Drug Price Negotiation: Permanent Framework Proposed, Combo Drug Gaming Rule Added
CMS proposed shifting the Medicare Drug Price Negotiation Program from guidance-based to codified rulemaking, establishing a permanent statutory framework. A companion proposal closes a loophole allowing manufacturers to pair drugs into combinations to reset negotiation timelines. Together the proposals represent a significant hardening of the negotiation architecture ahead of the program’s expansion to additional drugs in 2026 and 2027.
Source(s): Fierce Healthcare; Becker’s Hospital Review; InsideHealthPolicy
Tags: #DRUG #PAYER
Medicare: Drug Pricing Policy, Trust Fund, and MA Spending
A poll finds cross-party voter support above 70% for most-favored-nation drug pricing commitments — with direct midterm positioning implications. The Trump administration is separately revisiting a proposed rule to close a Medicare drug negotiation loophole manufacturers have used to reformulate drugs and reset negotiation timelines. On the trust fund, the 2026 Medicare Trustees Report maintains the 2033 Hospital Insurance Fund insolvency estimate — one quarter sooner than 2025 — and flags Medicare Advantage enrollment and spending growth as contributing factors.
Source(s): InsideHealthPolicy; STAT News; InsideHealthPolicy; KFF Health News; Becker’s Hospital Review
Tags: #PAYER #DRUG
CMS Tightens Accrediting Body Oversight
CMS finalized a rule June 12 increasing oversight of the nine accrediting organizations — including The Joint Commission — that survey more than 9,000 Medicare-certified facilities, introducing new reporting requirements and performance monitoring.
Source(s): Becker’s Hospital Review; KFF Health News
Tags: #HOSPITAL #PROVIDER
CMS Creates Office of Health Technology and Products
CMS established a new Office of Health Technology and Products, led by Deputy Administrator Amy Gleason, to centralize oversight of AI integration, digital health tools, and data interoperability across Medicare and Medicaid programs.
Source(s): ; Healthcare Dive; Becker’s Hospital Review
Tags: #ALL
Medicare Remote Patient Monitoring: Coverage Without Proven Benefit
Medicare covers remote patient monitoring for patients discharged after serious hospitalizations, but a new study associates these programs with increased readmissions — raising direct questions about the evidence basis for the benefit.
Source(s): MedPage Today
Tags: #PAYER #PROVIDER
Medicaid Roundup
Medicaid Section 1115 Demonstrations: Stricter Budget Neutrality Framework
CMS released guidance requiring Chief Actuary certification that Section 1115 demonstrations are budget neutral before approval, effective January 1, 2027. States characterized the change as adding administrative burden to an already complex approval process; CMS framed it as fiscal stewardship of the roughly one-third of all federal Medicaid dollars flowing through demonstration projects. (CMS · Becker’s Hospital Review · Healthcare Dive · Health Management Associates)
Medicaid State Directed Payments: $100B Baseline Before New Caps
KFF published a three-part analysis establishing the baseline for federal SDP spending before the reconciliation law’s new limits take effect. Across 40 states and D.C., SDP spending approaches $100 billion annually — a figure the new caps will significantly reshape, with CMS estimating $510 billion in federal spending reductions over 2026–2035. (KFF Research · KFF Research · KFF Research)
Medicaid Program Integrity: Federal Actions, State Strain, Disability Impact
Georgetown’s Center on Children and Families characterized the OIG’s formal action against Hawaii’s Medicaid program as weaponizing fraud authority against states. KFF documented the breadth of recent federal integrity actions. STAT News documented the downstream harm: people with disabilities reporting disruptions in home and community-based care as states implement the enforcement framework, with service gaps already occurring before work requirement implementation begins. More than 2 million fewer children are enrolled in Medicaid and CHIP since January 2023, with declines accelerating in 2026. (KFF Research · STAT News · Georgetown CCF)
EPSDT: CMS Updates Playbook After a Decade
CMS released an updated state playbook for the Early and Periodic Screening, Diagnostic, and Treatment benefit — the first significant revision in a decade. (Georgetown CCF)
Tags: #PATIENT #PAYER
Food and Drug Administration (FDA)
FDA Rare Disease Engagement: Advocates Push for More Predictable Trial Standards
Rare disease advocates pressed FDA for more predictable clinical trial standards, arguing the agency’s case-by-case approach to endpoint selection and trial design creates unsustainable uncertainty. FDA committed to increased engagement but stopped short of framework commitments.
Source(s): InsideHealthPolicy; InsideHealthPolicy
Tags: #DRUG #PROVIDER
Department of Health and Human Services (HHS)
RFK Jr.: Pushback, Departure Rumors, and Staff Skepticism
A week of intensifying scrutiny around Secretary Kennedy produced several distinct threads. The AMA moved toward formally distancing itself from his leadership. Kennedy publicly attacked the journalist behind a Times report that he appears “checked out,” then claimed his official calendar is publicly available — a claim STAT News investigated and found unsupported after a year of unanswered records requests. HHS officially denied circulating rumors of a July departure. POLITICO reported Kennedy has made overtures toward career staff, with split results: some describe improved conditions, others say their work has become harder.
Source(s): POLITICO Pulse; KFF Health News; STAT News; InsideHealthPolicy; POLITICO Health Care
Tags: #ALL
AI in Health: Surging Deployment, Mounting Governance Gaps
AI use jumped 148% at FDA in 2025 and grew across HHS — though analysts note some use cases appear designed to satisfy executive order compliance rather than operational need. A separate analysis finds most health AI tools in active deployment, including clinical scribes and prior authorization algorithms, fall outside existing regulatory oversight frameworks. Health system leaders express skepticism about AI physicians while supporting AI for access expansion.
Source(s):
Fierce Healthcare; Becker’s Hospital Review; Becker’s Hospital Review
Tags: #ALL
340B: Siphoning Suits, Rebate Fight Escalates, Washington State Court Ruling
Hospital systems in Kansas, Michigan, and New York filed suits alleging CVS Health is systematically siphoning 340B savings through its pharmacy benefit operations. Becker’s tracked 14 escalation points in the broader 340B rebate fight across covered entities, manufacturers, PBMs, and HRSA. A federal judge separately denied a bid from Novartis, AbbVie, and PhRMA to block Washington State’s 340B law before it took effect June 11.
Source(s): InsideHealthPolicy; Becker’s Hospital Review; Becker’s Hospital Review
Tags: #DRUG #HOSPITAL
NIH: Bethesda Declaration Anniversary and Grants Cap Debate
A year after 71 NIH staffers published the Bethesda Declaration protesting political interference in research, the signatories say leadership has largely ignored their concerns and conditions have worsened. The declaration’s authors published a statement lamenting continued destruction of NIH’s research independence. In parallel, NIH’s proposal to cap active grants per principal investigator drew mixed reactions — supporters argue it would spread funding more broadly; critics contend it would disrupt productive labs and disproportionately affect early-career researchers.
Source(s): STAT News; InsideHealthPolicy; InsideHealthPolicy; STAT News
Tags: #ALL
ACOG Breaks from CDC on COVID and Maternal Immunization
The American College of Obstetricians and Gynecologists issued vaccine recommendations diverging from CDC guidance on COVID-19 vaccination for pregnant patients and the broader maternal immunization schedule — the first time a major specialty society has published a competing immunization schedule.
Source(s): InsideHealthPolicy; The Hill; Becker’s Hospital Review
Tags: #PROVIDER #PATIENT
Heard on the Hill
Price Transparency: HHS Enforcement and Congressional Hearing
HHS sent formal warnings to 519 hospitals to post machine-readable price files or face financial penalties, signaling the end of the grace period on enforcement. A House Energy and Commerce Subcommittee hearing the same week examined why compliance remains incomplete years after the original rule, with witnesses pressing for stronger enforcement. HFMA noted growing bipartisan convergence on the issue.
- White House warns 500+ hospitals to post price information or face fines
- Health Subcommittee Holds Hearing to Examine Policies Increasing Price Transparency
- A chat with HFMA UK, plus the latest in price transparency with Turquoise Health
Tags: #HOSPITAL #PAYER
House Committee Moves to Block Medicare AI Prior Authorization Pilot
The House Appropriations Committee unanimously approved an amendment June 9 to bar CMS from funding the Wasteful and Inappropriate Service Reduction (WISeR) model, an AI-driven prior authorization pilot — reflecting bipartisan concern about automated denial tools.
Source(s): Healthcare Dive
Tags: #PAYER #PROVIDER
Notable Notes
AMA Annual Meeting: Drug Pricing, AI, 340B, and Scope of Practice
The AMA House of Delegates convened this week against a politically charged backdrop. The AMA endorsed several drug pricing policies but stopped short of fully endorsing most-favored-nation pricing. Delegates adopted policies requiring physician oversight of AI tools in clinical settings. On 340B, the AMA declined to endorse 340B-priced drugs for independent practice patients amid ongoing litigation. The AMA voted to fund comparative studies of physician versus nurse practitioner and physician assistant care in response to scope-of-practice expansion legislation in multiple states.
- AMA Endorses Drug Pricing Policies, Not Yet Sold On MFN
- AMA Adopts Policies Calling For Physician Oversight Of AI Tools
- AMA Holds Off On Endorsing 340B-Priced Drugs For Private Practice Patients
- AMA to Fund Studies Comparing Care From Physicians vs NPs, PAs
Tags: #PROVIDER #DRUG
JACC:CI June 2026: Leaflet Modification in TAVR — Four Papers
JACC: Cardiovascular Interventions’ June 8 issue published four coordinated papers advancing the evidence base for BASILICA and related leaflet modification techniques in TAVR.
- Aortic Valve Leaflet Modification: A Working Group Position Statement — Rogers, Greenbaum, Lederman et al.; step-by-step CT risk assessment and procedural guidance aimed at expanding operator adoption
- Impact of Leaflet Modification on HALT After Valve-in-Valve TAVR — Leipzig Heart Center; leaflet modification associated with significantly lower hypoattenuated leaflet thickening (19.7% vs. 40%; P<0.01); no HALT in dual-leaflet modification patients
- CT-Based Risk Stratification of Coronary Obstruction During TAVR — novel volumetric parameter (VTCV) outperforms VTC distance in predicting obstruction despite coronary protection; validated across 11 European centers
- Leaflet Splitting in Stented vs. Stentless Surgical Bioprosthetic Valves — EURO-BASILICA registry; stentless valves had significantly higher partial coronary obstruction rate (44.4% vs. 7.1%)
Tags: #DEVICE #PROVIDER
Mitral TEER: New Echo Guideline Standardizes Procedural Approach
A new guideline establishes standardized echocardiographic guidance for mitral transcatheter edge-to-edge repair, covering patient selection, procedural monitoring, and post-procedure assessment.
Source(s): Cardiovascular Business
Tags: #DEVICE #PROVIDER
CT-FFR Standardized in New SCCT-SCAI Consensus Statement
The Society of Cardiovascular Computed Tomography and SCAI published a consensus statement establishing standardized guidance for CT-derived fractional flow reserve, marking the maturation of CT-FFR from investigational tool to guideline-supported modality.
Source(s): Cardiovascular Business
Tags: #DEVICE #PROVIDER
Montana: Doctors Leave Hospital After Questioning TAVR Patient Selection
Physicians left Benefis Health System in Great Falls, Montana following disputes over patient selection criteria for the hospital’s TAVR program — a program integrity story with implications for how community TAVR programs manage quality oversight and physician governance.
Source(s): Montana Free Press
Tags: #DEVICE #PROVIDER
FTC vs. PBMs: Insulin Rebate Settlements Near Completion
UnitedHealth Group’s Optum Rx reached a tentative settlement with the FTC over insulin rebate practices June 12, following CVS earlier this year and Express Scripts in February. Together the three settlements effectively wind down federal rebate litigation against all major PBMs — though the structural questions about rebate practices and their effect on insulin list prices remain matters of active legislative debate.
Source(s):
Fierce Healthcare
Healthcare Dive
Becker’s Hospital Review
Tags: #DRUG #PAYER
Hospital Operations and Cost Outlook
Healthcare costs are projected to grow 9% in 2027, with insurance premiums and home care costs rising sharply; hospital associations simultaneously oppose CMS’s proposed 2027 reimbursement update. Administrative costs now consume 25–35% of total US health spending. ED volumes are surging and health systems are adding digital diversion tools. Provider-sponsored health plans are being reassessed amid Medicare Advantage instability. The $50 billion Congress earmarked for rural health falls far short of the $160 billion in combined Medicaid, ACA, and SNAP cuts the same law imposes on rural communities.
- Outlook For 2027: Insurance Premiums And Home Care Costs To Rise Sharply
- Hospital Groups Urge CMS To Set Higher Pay Rates Next Year
- Administrative costs now eat 25% to 35% of US health spending
- Amid ED surge, hospitals add diversion tools
- Not dead: Provider-sponsored plans reassessing
- Rural health’s $50B won’t cover $160B in HR 1 cuts
Tags: #HOSPITAL #PAYER